DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

October 3, 2006

Susan Olinger
B. Braun Medical, Inc.
901 Marcon Boulevard
Allentown, Pennsylvania 18109

Dear Ms. Olinger:

Your petition requesting the Food and Drug Administration to determine whether Cefotan (cefotetan injection), equivalent 1 g ADD-vantage vial and 2 g ADD-vantage vial, NDAA 63-293, manufactured by AstraZeneca has been voluntarily withdrawn from sale for safety and efficacy reasons, was received by this office on 10/02/2006. It was assigned docket number 2006P-0404/CP 1 and it was filed on 10/02/2006. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Gloria Ortega

Gloria Ortega, Deputy Director
Division of Dockets Management
Office of Management Programs
Office of Management

2006P-0404

ACK 1